Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized phase2 Study of IP vs. GP as the First-line Therapy Followed by Two Different Sequences as the 2nd or 3rd-line Therapy for Patients With Advanced NSCLC;

NCT01003964 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT01003964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01003964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized phase2 Study of IP vs. GP as the First-line Therapy Followed by Two Different Sequences as the 2nd or 3rd-line Therapy for Patients With Advanced NSCLC;
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
June 30, 2015
Enrollment
289 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer